Your browser is no longer supported. Please, upgrade your browser.
Eiger BioPharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.44 Insider Own0.10% Shs Outstand29.88M Perf Week-11.49%
Market Cap308.52M Forward P/E- EPS next Y-1.58 Insider Trans-4.82% Shs Float27.65M Perf Month-12.33%
Income-63.20M PEG- EPS next Q0.25 Inst Own75.00% Short Float5.73% Perf Quarter2.44%
Sales- P/S- EPS this Y19.30% Inst Trans5.88% Short Ratio4.01 Perf Half Y-17.28%
Book/sh3.11 P/B2.97 EPS next Y-14.50% ROA-57.80% Target Price- Perf Year1.54%
Cash/sh3.75 P/C2.46 EPS next 5Y- ROE-100.60% 52W Range4.55 - 13.99 Perf YTD-24.82%
Dividend- P/FCF- EPS past 5Y17.00% ROI- 52W High-33.95% Beta1.47
Dividend %- Quick Ratio6.20 Sales past 5Y- Gross Margin- 52W Low103.08% ATR0.68
Employees29 Current Ratio6.20 Sales Q/Q- Oper. Margin- RSI (14)34.86 Volatility5.81% 6.16%
OptionableYes Debt/Eq0.33 EPS Q/Q31.10% Profit Margin- Rel Volume0.87 Prev Close10.01
ShortableYes LT Debt/Eq0.27 Earnings- Payout- Avg Volume394.87K Price9.24
Recom1.00 SMA20-16.94% SMA50-15.76% SMA200-11.17% Volume344,545 Change-7.69%
Jun-26-19Initiated Citigroup Buy $22
Jan-29-19Initiated Robert W. Baird Outperform $47
May-09-18Initiated B. Riley FBR, Inc. Buy $24
Jan-03-18Initiated Ladenburg Thalmann Buy $32
Oct-19-17Initiated ROTH Capital Buy $35
Jun-21-17Resumed Wedbush Outperform $28 → $34
Feb-23-21 11:07AM  
Feb-08-21 08:00AM  
Jan-25-21 08:00AM  
Jan-07-21 08:00AM  
Jan-06-21 11:00AM  
Dec-24-20 06:49AM  
Nov-25-20 08:42AM  
Nov-24-20 03:10PM  
Nov-23-20 08:00AM  
Nov-20-20 05:53PM  
Nov-17-20 08:00AM  
Nov-16-20 04:05PM  
Nov-11-20 08:00AM  
Nov-05-20 04:05PM  
Nov-02-20 04:30PM  
Oct-16-20 10:01AM  
Oct-15-20 03:24PM  
Sep-29-20 07:42AM  
Sep-28-20 03:47PM  
Sep-15-20 08:54AM  
Sep-09-20 09:36AM  
Sep-01-20 08:00AM  
Aug-31-20 08:00AM  
Aug-19-20 08:49AM  
Aug-17-20 07:40AM  
Aug-06-20 04:05PM  
Aug-03-20 08:00AM  
Jul-17-20 12:16PM  
Jul-12-20 08:14PM  
Jul-08-20 12:00PM  
Jun-24-20 08:32AM  
Jun-08-20 01:22PM  
May-29-20 04:05PM  
May-26-20 04:05PM  
May-19-20 04:05PM  
May-15-20 08:57AM  
Apr-30-20 08:00AM  
Apr-22-20 10:05AM  
Apr-09-20 06:08PM  
Apr-01-20 04:05PM  
Mar-24-20 10:25AM  
Mar-23-20 08:00AM  
Mar-20-20 06:45AM  
Mar-13-20 08:00AM  
Jan-19-20 03:04PM  
Jan-15-20 05:24AM  
Jan-07-20 08:00AM  
Jan-06-20 08:00AM  
Dec-16-19 05:15PM  
Dec-07-19 01:33AM  
Nov-15-19 08:00AM  
Nov-12-19 08:45AM  
Nov-11-19 09:58AM  
Nov-07-19 04:05PM  
Oct-21-19 09:00AM  
Oct-09-19 09:47AM  
Sep-27-19 08:00AM  
Aug-29-19 04:05PM  
Aug-20-19 08:00AM  
Aug-08-19 04:05PM  
Aug-05-19 08:00AM  
Jul-31-19 08:00AM  
Jul-18-19 09:20AM  
Jul-11-19 12:42PM  
Jul-08-19 09:00AM  
Jun-20-19 07:08PM  
Jun-18-19 07:31AM  
Jun-17-19 04:16PM  
Jun-10-19 08:00AM  
Jun-05-19 08:00AM  
May-30-19 08:00AM  
May-17-19 04:05PM  
May-09-19 05:04PM  
Apr-30-19 08:00AM  
Apr-26-19 02:43PM  
Apr-23-19 03:50PM  
Apr-17-19 10:53PM  
Apr-15-19 08:00AM  
Apr-11-19 04:05PM  
Mar-26-19 08:00AM  
Mar-25-19 01:30PM  
Mar-20-19 08:00AM  
Mar-15-19 09:04AM  
Mar-14-19 04:19PM  
Mar-13-19 08:00AM  
Mar-11-19 08:00AM  
Mar-08-19 07:37PM  
Mar-04-19 07:00AM  
Feb-27-19 08:00AM  
Feb-06-19 08:00AM  
Feb-04-19 08:00AM  
Jan-07-19 08:00AM  
Dec-31-18 07:30AM  
Eiger BioPharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase 3 clinical trial to treat hepatitis delta virus (HDV) infection. The company's product candidate also include Lambda, which targets type III interferon receptors that is in Phase 2 clinical trial; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide that has completed phase 2 clinical trial to treat post-bariatric hypoglycemia, as well as in phase 2 clinical trial for the treatment of congenital hyperinsulinism. The company is headquartered in Palo Alto, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mayer Eldon C. IIIEx VP & Chief Commerc. OfficerJan 08Sale11.681,69019,73935,810Jan 11 06:10 PM
Glenn Jeffrey SDirectorAug 12Buy11.425,00057,1035,000Aug 12 06:28 PM
Glenn Jeffrey SDirectorAug 11Buy11.495,00057,46371,355Aug 12 06:28 PM
Dietz Thomas JohnDirectorMar 16Buy4.951,0004,95030,000Mar 17 05:17 PM
Glenn Jeffrey SDirectorMar 16Buy5.0330,000150,81366,355Mar 17 05:16 PM